» Articles » PMID: 30774270

Contribution of Ghrelin to Functional Gastrointestinal Disorders' Pathogenesis

Overview
Specialty Gastroenterology
Date 2019 Feb 19
PMID 30774270
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Functional gastrointestinal disorders (FGID) are heterogeneous disorders with a variety of clinical manifestations, primarily defined by signs and symptoms rather than a definite underlying cause. Their pathophysiology remains obscure and, although it is expected to differ according to the specific FGID, disruptions in the brain-gut axis are now thought to be a common denominator in their pathogenesis. The hormone ghrelin is an important component of this axis, exerting a wide repertoire of physiological actions, including regulation of gastrointestinal motility and protection of mucosal tissue. Ghrelin's gene shows genetic polymorphism, while its protein product undergoes complex regulation and metabolism in the human body. Numerous studies have studied ghrelin's relation to the emergence of FGIDs, its potential value as an index of disease severity and as a predictive marker for symptom relief during attempted treatment. Despite the mixed results currently available in scientific literature, the plethora of statistically significant findings shows that disruptions in ghrelin genetics and expression are plausibly related to FGID pathogenesis. The aim of this paper is to review current literature studying these associations, in an effort to uncover certain patterns of alterations in both genetics and expression, which could delineate its true contribution to FGID emergence, either as a causative agent or as a pathogenetic intermediate.

Citing Articles

Molecular Mechanisms behind Obesity and Their Potential Exploitation in Current and Future Therapy.

Nicze M, Dec A, Borowka M, Krzyzak D, Boldys A, Buldak L Int J Mol Sci. 2024; 25(15).

PMID: 39125772 PMC: 11311839. DOI: 10.3390/ijms25158202.


Novel Pharmaceuticals in Appetite Regulation: Exploring emerging gut peptides and their pharmacological prospects.

Rubinic I, Kurtov M, Likic R Pharmacol Res Perspect. 2024; 12(4):e1243.

PMID: 39016695 PMC: 11253306. DOI: 10.1002/prp2.1243.


Postprandial effect of gastrointestinal hormones and gastric activity in patients with irritable bowel syndrome.

Furgala A, Ciesielczyk K, Przybylska-Felus M, Jablonski K, Gil K, Zwolinska-Wcislo M Sci Rep. 2023; 13(1):9420.

PMID: 37296188 PMC: 10256731. DOI: 10.1038/s41598-023-36445-1.


Role of the Ghrelin System in Colorectal Cancer.

Kasprzak A Int J Mol Sci. 2022; 23(10).

PMID: 35628187 PMC: 9141034. DOI: 10.3390/ijms23105380.


One Giant Leap from Mouse to Man: The Microbiota-Gut-Brain Axis in Mood Disorders and Translational Challenges Moving towards Human Clinical Trials.

Forssten S, Ouwehand A, Griffin S, Patterson E Nutrients. 2022; 14(3).

PMID: 35276927 PMC: 8840472. DOI: 10.3390/nu14030568.


References
1.
Talley N . Scope of the problem of functional digestive disorders. Eur J Surg Suppl. 1999; (582):35-41. DOI: 10.1080/11024159850191427. View

2.
Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K . Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402(6762):656-60. DOI: 10.1038/45230. View

3.
Takaya K, Ariyasu H, Kanamoto N, Iwakura H, Yoshimoto A, Harada M . Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab. 2001; 85(12):4908-11. DOI: 10.1210/jcem.85.12.7167. View

4.
Wren A, Seal L, Cohen M, Brynes A, Frost G, Murphy K . Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab. 2001; 86(12):5992. DOI: 10.1210/jcem.86.12.8111. View

5.
Date Y, Nakazato M, Hashiguchi S, Dezaki K, Mondal M, Hosoda H . Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes. 2002; 51(1):124-9. DOI: 10.2337/diabetes.51.1.124. View